NEW YORK () -- Valeant Pharmaceuticals ( - ) stock is down by 5.34% to $168.08 in mid-morning trading on Monday, after the company reported its 2015 third quarter earnings results and raised its full-year guidance.
The pharmaceutical and medical device company reported earnings of $2.74 per share, up from $2.11 per share for the 2014 third quarter.
Revenue increased by 36% year over year, to $2.8 billion for the most recent quarter.
STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks with serious upside potential.
Valeant Pharmaceuticals had been forecast to report earnings of $2.72 per share on revenue of $2.78 billion by...